Irish Consortium to Develop Novel Treatment for ARDS Caused by COVID19

NUI Galway, OmniSpirant Limited and Aerogen Limited have been awarded major funding to develop a new aerosol treatment with potential benefits across acute and chronic lung diseases, including COVID-19

An Irish consortium involving NUI Galway, OmniSpirant Limited, a start-up biotechnology company and Aerogen Limited, have been awarded €11.6 million under the Disruptive Technologies Innovation Fund (DTIF).